Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.

Abstract: Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders and syndromes. Such MECP2 associated disorders include MECP2 duplication syndrome.

Abstract: Embodiments of the disclosure concern cell therapy methods and compositions utilizing cells expressing at least a chimeric TGF? receptor including the exodomain of a TGF?II receptor and an endodomain that is not from TGF? receptor, thereby converting the negative signal of TGF? for T cell proliferation into a T cell activation signal. In at least certain aspects, cells harboring the chimeric TGF? receptor also harbor one or more chimeric antigen receptors.

Abstract: Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods of their use as cardioprotective agents are provided. The small molecule stimulators are useful for promoting cardiac protection and repair and vascular regeneration after myocardial infarction. The compounds are also useful in preventing cardiac hypertrophy and collagen deposition and improving cardiac post-infarction function.

Abstract: Certain embodiments provide methods and compositions related to clinical management of cancer patients based on the expression level of TMCO3. Further embodiments involve methods and compositions related to treatment of cancer patients or patients determined to have an increased TMCO3 level relative to a control or a reference level that is normal or indicating favorable prognosis.

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

Abstract: A series of benzosuberene analogues demonstrate effective inhibition of tubulin polymerization, cytotoxicity against human cancer cell lines, and vascular disruption in tumors.

Abstract: The present disclosure provides an orthopedic device and method for carpal fusion that provides bone to bone compression and multiple fixation points to decrease multiple degrees of freedom and motion of carpal bones. The device is biocompatible, resistant to corrosion, and sufficient in mechanical strength. Bone to bone compression and fixation points can be increased by using a first set of fasteners in a peripheral portion of the device to couple through the device into bone structure, and a second set of fasteners in a central portion of the device can be coupled through the device into the bone structure.

Abstract: Disclosed are compositions and methods related to rendering ineffective Th1 T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. Tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Th1 immunostimulatory/activating signal. The T cells employ a chimeric antigen receptor having exodomains for IL10, IL13 and/or IL4 fused with the signal transducing endodomains for IL2 and/or IL7.

Abstract: An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm2 if the growth surface is not comprised of gas permeable material and up to 2 ml/cm2 if the growth surface is comprised of gas permeable material. The desired cells are at a surface density of less than 0.5×106 cells/cm2 at the onset of a production cycle, and the surface density of the desired cells plus the surface density of the antigen presenting cells and/or feeder cells are at least about 1.25×105 cells/cm2.

Abstract: One aspect of the invention provides and artificial, flexible valve indlucding: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. The plurality of leaflets form a plurality of coaptation regions between two adjacent leaflets. The coaptation regions include extensions along a z-axis and adapted and are configured to form a releasable, but substantially complete seal when the leaflets are in a closed position. Another aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. Each of the plurality of leaflets terminates in a commissure line. The commissure lines devi-ate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.

Abstract: The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis.

Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).

Abstract: The present invention relates to compositions and methods of treating lysosomal storage diseases and methods of using trehalose.

Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.

Abstract: The disclosure provides a system and a method for reducing hazardous gases, including PHGs, through one or more photocatalysts in a filter system. A microstructure of the photocatalytic filter can be formed using biological systems as a template for the photocatalysts to be deposited thereon. The biological system can be removed by heat, oxidation, or by chemical processes to leave the photocatalytic template as a filter for the gases. In various embodiments, multiple photocatalysts can be activated at different wavelengths to filter different gases, or multiple photocatalysts can be activated at the same wavelength to filter different gases, or a photocatalyst can be activated at different wavelengths to filter different gases, or some combination thereof. The activation can be sequential or concurrent. For multiple layers of photocatalysts, the sequence of the photocatalysts can be arranged to reduce damaging output from an upstream photocatalyst to one or more downstream photocatalysts.

Abstract: The present disclosure provides a system and method for an ultrathin optical metasurface with an array patterning formed on an optical fiber facet that enables manipulation of light passing therethrough, such as focusing and steering the light, and controlling a polarization state of light. The patterning can be non-uniform to selectively direct light passing through the metasurface. Array structures can vary in size, angle, shapes, and other non-uniform aspects. Further, the array can include materials that can be electrically activated and controlled to variably tune the metasurface characteristics for increased ability to manipulate the light passing therethrough. The materials can include a conductor, a dielectric, or a composite of a conductor, insulator, and dielectric formed on the optical fiber.

Abstract: One aspect of the invention provides a mobile clinic including: an intermodal container defining at least a first opening and a second opening; a partition wall located within the intermodal container, the partition wall separating the intermodal container into an anteroom and a treatment room; and an access control device programmed to prevent passage from the anteroom into the treatment room until a user's donning of personal protective equipment is verified. Another aspect of the invention provides a collapsible structure including: a rigid base; a rigid roof; one or more collapsible walls extending between the floor and the base; and an erector system comprising four cross-bars. Another aspect of the invention provides a crate including: a bottom panel; a top panel; and a plurality of walls, wherein at least two of said plurality of walls including one or more conduits.

Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor, and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.

Abstract: A disclosed system quantifies the power distribution of a wireless signal within a constrained environment using non-sequential ray tracing. For each ray, one or more ray-reflecting surface is prescreened to identify collision-eligible surfaces and identify a collision surface from the collision-eligible surfaces, wherein the collision surface is the first ray-reflecting surface that a ray collides with. A power distribution component, indicating the position and power of a ray at a particular elevation within the environment, is added to a cumulative power distribution. If a reflected ray corresponding to each collision is calculated and satisfies ray eligibility conditions, a collision surface may be determined for the reflected ray. Collision surfaces may be identified by evaluating a target function for a number of ray positions, where the target function evaluates to zero when displacement between the ray and the ray-reflecting surface is zero.